Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
In blow to Lula, Brazil Congress revives controversial environmental bill - 2Favored Vehicle for Seniors: Make Your Determination
- 3Tablets: Upgrade Your Understanding Experience
- 4The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- 5Bestselling author Colleen Hoover reveals cancer journey
- What really happens when 140 reality stars come face to face with their biggest fans
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- Ariana Grande says Eternal Sunshine 2026 tour will be her last for a 'long, long time': 'One last hurrah'
- What to know about King Charles III's cancer treatment and his message to the public
- Excelling at Cash The board: A Manual for Monetary Essentials
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- The most effective method to Pick the Right Material Organization: Fundamental Tips
